- Market 360: The Best and Worst of the Week for US Equities, Commodities, Currencies, and More
- The Dow, S&P and NASDAQ are all positive for the week, with the NASDAQ in the lead gaining over 3%.
- Stocks Start to Hit a Wall: Here's What You Can Do
- Paulson: Economy Is Better But Housing Still a Threat
- Ryanair CEO Says Downturn Good for the Company
- Credit Problems Spreading Beyond Mortgages: FDIC
- Bonds Gain Following Weak Consumer Sentiment Reading
- Consumer Sentiment Falls To Lowest Level in 28 Years
- How To Prosper On Retiring Boomers
- Goldman Forecasts $141 Oil For Second Half of Year
- Welcome To "Trading Chicago Hope"
- Your First Move For Monday May 19th
- Web Extra: Windy City Whale Watching
- Lightning Round OT: Schlumberger, Wellcare and More
- Chicago Turnaround Story?
- Surprise Friday – Guess Our Chicago Guest
- Measuring Google's Success
- Pops & Drops: Abbott Labs, Starbucks...
- Life Is Good In The Pits
- Chicago Ag Trades
- Calif. wine patriarch Robert Mondavi dies at 94
- Alabama sheriffs feed inmates on $1.75 a day
- UAW, American Axle reach deal that may end strike
- Bush fails to win Saudi help on gas prices
- UAW, American Axle reach deal that could end strike
- USA Swimming hopes for swimsuit case settlement
- Canada scraps development of medical isotope reactors
- Texas officials sue US over border fence
- Dollar falls against pound in late trading
- Dollar flat against Swiss franc in late trading
Watchlist Sponsored By :
Procter & Gamble gets approval for new Actonel dose
Font size:
CINCINNATI (AP) - Consumer products company Procter & Gamble Co. said Thursday the Food and Drug Administration approved a once-a-month version of its osteoporosis drug Actonel.
Osteoporosis is a condition that causes weak bones that are more likely to fracture over time. The drug was first approved by the FDA in 2000 and is now made in several doses. The latest approval is for a 150-milligram dose.
Shares of Procter & Gamble fell 34 cents to $66.83.
Copyright 2008 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Tools:
Print
Email
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes